Human Papillomavirus Associated CarcinomasCervical CancerHead and Neck CancersAnal CancerVulva CancerVaginal CancerPenile CancerHPV-Related Malignancy
Investigational drug(s) / intervention(s)
SCG142 TCR-T cells
SCG142 TCR-T cells: Monotherapy of SCG142
Study summary
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria:
1. Greater than or equal to 18 years of age
2. HPV associated carcinomas
3. Patients must have at least one measurable lesion defined by RECIST 1.1
4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Key Exclusion Criteria:
1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
2. Patients with active autoimmune diseases.
3. Patient has a known active Hepatitis B or Hepatitis C.
4. Other severe medical conditions that may limit subject\'s participation in this trial.
Primary outcome measure(s)
DLT — 28 days Number of subjects with adverse events (AEs) and laboratory abnormalities defined as dose limiting toxicities (DLT)
Trial sites (1)
Facility
City
Region
Status
The affiliated hosptial of qingdao university
Qingdao
Shandong
Recruiting
More The Affiliated Hospital of Qingdao University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.